Substances
Is Lyrica a Controlled Substance? A Usage & Scheduling Guide

Medically Reviewed By
Dr. Po-Chang Hsu, M.D., M.S
On July 14, 2025

Written By
Amanda Stevens, BS
Updated On July 14, 2025
Substances
Medically Reviewed By
Dr. Po-Chang Hsu, M.D., M.S
On July 14, 2025
Written By
Amanda Stevens, BS
Updated On July 14, 2025
A controlled substance is any compound regulated at the federal level by the government due to its potential for dependency, abuse, and addiction. Controlled substances are categorized into “schedules” by the DEA, from Schedule I through Schedule V. The category or schedule each substance is put into is based on its medical utility, safety & toxicity profiles, abuse potential, and more.[1] Schedule V drugs are considered the “lowest” category in terms of restriction, and Schedule I is the most restrictive category.
Pregabalin is the generic name for Lyrica, and it’s classified as a Schedule V controlled substance.[2] Schedule V drugs have a lower potential for abuse compared to other schedules; however, the potential is still significant enough to justify caution on the federal level. With Schedule V, the substances typically require controlled distribution because misuse can still cause both physical and psychological dependence.
Lyrica is classified as a Schedule V substance due to the potential for dependency, particularly with long-term use or among those who misuse the substance, knowingly or not. Even though it’s considered far safer than many other narcotics, healthcare providers are still bound by federal law to follow regulatory prescription guidelines.
These guidelines ensure that prescriptions of Lyrica are monitored. Prescribers need to follow specific dispensing regulations that dictate the dosage and refill frequency to minimize the risk of dependence or abuse. Pharmacies also need to keep detailed records for federally scheduled substances, typically tracking prescriptions for compliance and to prevent diversion or misuse.
For patients, it’s critical to know that long-term Lyrica use can reinforce dependency. For many, just knowing that it’s on the list of federally controlled narcotics is enough to stress how important it is to stick to the prescribed dosage amount and frequency.
Patients should avoid sharing Lyrica with anyone else, even others with a prescription, since dosages can vary from person to person. For anyone without a valid prescription, unauthorized possession, use, or distribution of Lyrica can result in substantial penalties, which may include federal charges, fines, and imprisonment.
Lyrica is an approved treatment for several conditions related to neurology and pain, making it a versatile option in clinical practice. The three biggest use cases are neuropathic pain, fibromyalgia, and seizure management. Lyrica binds to voltage‑gated calcium channels in nerve terminals, similar to how gabapentin works, reducing the release of excitatory neurotransmitters that signal nerve pain. This is also known as GABA-ergic signaling. It’s most commonly prescribed for peripheral neuropathy and postherpetic neuralgia.[3]
Both Lyrica and gabapentin are GABA analogs, which gives them a wide range of “off-label” use as treatments for chronic pain. However, Lyrica’s Schedule V status is a good indication of its slightly higher potential for addiction compared to gabapentin.
Fibromyalgia is another primary condition treated by Lyrica, and is characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory, and mood issues. Lyrica is one of the few medications FDA‑approved to manage fibromyalgia symptoms. In clinical trials, patients experienced significant reductions in pain scores and improvement in sleep quality. [4]
Originally approved as an anticonvulsant, Lyrica also serves as an adjunctive therapy for partial-onset seizures in adults. Through a mechanism that modulates calcium influx at nerve terminals during nerve pain flare-ups, it helps decrease neuronal hyperexcitability, which contributes to seizure activity. When used with other antiepileptic drugs, Lyrica can reduce seizure frequency by up to 50% in some patients. [5]
While Lyrica provides measurable relief for neuropathic and seizure disorders, patients and providers still need to remain cognizant of safety cautions and proper use.
While it’s generally well-tolerated, there are some potential side effects and risks to be aware of if you’re using Lyrica, whether prescribed or not. The most commonly reported side effects include dizziness, somnolence, unintended weight gain, and peripheral edema. In most cases, these side effects are dose-dependent and are more noticeable during the initial titration period.
During this period, and until you’re familiar with how Lyrica impacts your alertness, you should avoid driving or operating any heavy machinery. It’s also important to regularly monitor your weight and any swelling you notice in your extremities to detect early signs of fluid retention.
As a federally scheduled controlled substance, Lyrica has a mild to moderate potential for misuse and abuse. Those with an established history of substance abuse or a diagnosis of substance use disorder will face a significantly higher risk of dependency.
Prescribers can help mitigate misuse by:
Additionally, as a mild CNS depressant, Lyrica can interact adversely with other depressants, particularly powerful ones like opioids, benzodiazepines, and alcohol. Combining Lyrica with other depressants can lead to dangerous sedation and a greatly elevated risk of respiratory depression. Lyrica is also contraindicated in patients who have a known hypersensitivity to pregabalin or its components.
Opioid medications like codeine typically have a much higher risk for dependence and respiratory depression. But Lyrica targets nerve pain with a more direct mechanism of action, without the need for acting on opioid receptors. This makes it a safer option for long-term management of neuropathic conditions. Codeine remains useful for acute pain flares, but its classification as an opioid demands stricter monitoring, making Lyrica safer and more versatile.
All substances in Schedule V have controlled prescription and distribution, and Lyrica is no exception. Both federal and state regulations aim to prevent misuse while ensuring that patients who require Lyrica as a treatment can still access it.
Only healthcare providers registered with the DEA are permitted to prescribe Lyrica, and many states also require a written or secure digital prescription e-signed by the prescriber. The refill limits on Schedule V substances typically limit patients to five refills within six months of the original prescription date, beyond which a new prescription is needed.
Pharmacists and pharmacy technicians are required to log every dispensation of Lyrica in their records. This records patient information, prescription dates, dispensed dosages, and the quantities dispensed. Providers and pharmacists are also required to consult the state Prescription Drug Monitoring Program before prescribing or dispensing Lyrica to identify any potential patterns of misuse or drug-seeking behavior like doctor shopping. Overall, these safeguards help create a framework where patients are kept as safe as possible, and providers are empowered to protect themselves from issuing dangerous or harmful prescriptions.
If you or someone you know is taking Lyrica, either prescribed or otherwise, it’s critical to understand the risks and addiction potential. Always ensure you adhere to the prescribed dosages and frequency, and consult a trusted healthcare professional for any questions about your treatment.
Making an effort to use Lyrica responsibly and being aware of potential signs of dependency can help you avoid issues while reaping the benefits of legitimate use. If you have any concerns about use or possible dependency and addiction, be sure to reach out to your prescriber or a trusted drug rehab for information and guidance.
Below are some of the most frequently asked questions regarding Lyrica.
[1] Authority and criteria for classification of substances. 21 USC 811: Authority and criteria for classification of substances. (n.d.). https://uscode.house.gov/view.xhtml?req=granuleid%3AUSC-prelim-title21-section811&num=0&edition=prelim
[2] Is Lyrica (pregabalin) a controlled substance / narcotic? (n.d.). Drugs.com. https://www.drugs.com/medical-answers/lyrica-controlled-substance-narcotic-3571636/
[3] Cappuzzo, K. A. (2009). Treatment of postherpetic neuralgia: Focus on Pregabalin. Clinical interventions in aging. https://pmc.ncbi.nlm.nih.gov/articles/PMC2685221/
[4] Derry, S., Cording, M., Wiffen, P. J., Law, S., Phillips, T., & Moore, R. A. (2016, September 29). Pregabalin for pain in fibromyalgia in adults. The Cochrane database of systematic reviews. https://pmc.ncbi.nlm.nih.gov/articles/PMC6457745/
[5] Panebianco, M., Bresnahan, R., & Marson, A. G. (2022). Pregabalin add-on for drug-resistant focal epilepsy. Cochrane Library, 2022(4). https://doi.org/10.1002/14651858.cd005612.pub5